Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseTomas Jernberg, Lars Wallentin, Christopher D. Payne et al.|European Heart Journal|2006Cited by 537
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics DifferentlyNazar Farid, Daniel E. Salazar, Joseph A. Jakubowski et al.|Clinical Pharmacology & Therapeutics|2007Cited by 323
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I studyChristoph Beglinger, Pharis Mohideen, Emmanuel Bouillaud et al.|Endocrine|2012Cited by 18